Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | CUE-102 |
Synonyms | |
Therapy Description |
CUE-102 is a fusion protein comprised of HLA molecules presenting WT1-derived peptide epitopes and affinity-attenuated IL-2, which potentially increases antitumor immune response against WT1-expressing tumors (Cancer Res (2020) 80 (16_Supplement): 6699). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
CUE-102 | CUE 102|CUE102 | CUE-102 is a fusion protein comprised of HLA molecules presenting WT1-derived peptide epitopes and affinity-attenuated IL-2, which potentially increases antitumor immune response against WT1-expressing tumors (Cancer Res (2020) 80 (16_Supplement): 6699). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05360680 | Phase I | CUE-102 | A Phase 1 in Patients With HLA-A*0201+ and WT1+ Recurrent/Metastatic Cancers | Active, not recruiting | USA | 0 |